New psoriasis drug bimekizumab outperforms secukinumab in major trial
NCT ID NCT03536884
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tested bimekizumab against secukinumab and placebo in 743 adults with moderate to severe plaque psoriasis. The main goal was to see how many patients achieved complete skin clearance (PASI100) at 16 weeks. Bimekizumab showed superior results compared to secukinumab, suggesting it may be a more effective treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bimekizumab
What this could lead to
If successful, bimekizumab could offer a more effective treatment option for people with moderate to severe plaque psoriasis, potentially clearing skin faster than current therapies.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all patients. Side effects and long-term safety are still being evaluated. Bimekizumab is not yet approved for psoriasis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
PS0015 3
Carlton, Australia
-
PS0015 6
Kogarah, Australia
-
PS0015 7
Hectorville, Australia
-
PS0015 9
Woolloongabba, Australia
-
Ps0015 11
Parkville, Australia
-
Ps0015 153
Toulouse, France
-
Ps0015 204
Witten, Germany
-
Ps0015 211
Hamburg, Germany
-
Ps0015 213
Mahlow, Germany
-
Ps0015 215
Lübeck, Germany
-
Ps0015 219
Münster, Germany
-
Ps0015 222
Tübingen, Germany
-
Ps0015 223
Augsburg, Germany
-
Ps0015 234
München, Germany
-
Ps0015 236
Neu-Ulm, Germany
-
Ps0015 237
Berlin, Germany
-
Ps0015 238
Mainz, Germany
-
Ps0015 263
Breda, Netherlands
-
Ps0015 265
Amsterdam, Netherlands
-
Ps0015 352
Gdansk, Poland
-
Ps0015 355
Bialystok, Poland
-
Ps0015 361
Bialystok, Poland
-
Ps0015 366
Katowice, Poland
-
Ps0015 368
Wroclaw, Poland
-
Ps0015 369
Bialystok, Poland
-
Ps0015 372
Lodz, Poland
-
Ps0015 375
Wroclaw, Poland
-
Ps0015 376
Krakow, Poland
-
Ps0015 377
Ostrowiec Świętokrzyski, Poland
-
Ps0015 378
Katowice, Poland
-
Ps0015 379
Krakow, Poland
-
Ps0015 450
Barcelona, Spain
-
Ps0015 451
Madrid, Spain
-
Ps0015 454
Madrid, Spain
-
Ps0015 455
Alicante, Spain
-
Ps0015 456
Madrid, Spain
-
Ps0015 457
Sant Joan Despí, Spain
-
Ps0015 50
Brussels, Belgium
-
Ps0015 52
Liège, Belgium
-
Ps0015 54
Brussels, Belgium
-
Ps0015 555
Salford, United Kingdom
-
Ps0015 559
Newcastle upon Tyne, United Kingdom
-
Ps0015 657
Waterloo, Canada
-
Ps0015 661
Peterborough, Canada
-
Ps0015 663
Mississauga, Canada
-
Ps0015 671
Hamilton, Canada
-
Ps0015 673
Halifax, Canada
-
Ps0015 677
Toronto, Canada
-
Ps0015 678
Richmond Hill, Canada
-
Ps0015 760
Kayseri, Turkey (Türkiye)
-
Ps0015 762
Istanbul, Turkey (Türkiye)
-
Ps0015 763
Gaziantep, Turkey (Türkiye)
-
Ps0015 900
West Des Moines, Iowa, 50265, United States
-
Ps0015 901
Portsmouth, New Hampshire, 03801, United States
-
Ps0015 903
Ocala, Florida, 34470, United States
-
Ps0015 915
Clayton, Missouri, 63105, United States
-
Ps0015 920
Portland, Oregon, 97210, United States
-
Ps0015 921
Ormond Beach, Florida, 32174, United States
-
Ps0015 924
Houston, Texas, 77004, United States
-
Ps0015 929
Portland, Oregon, 97223, United States
-
Ps0015 936
Tampa, Florida, 33613, United States
-
Ps0015 939
Danbury, Connecticut, 06810, United States
-
Ps0015 944
New Orleans, Louisiana, 70115, United States
-
Ps0015 953
St Louis, Missouri, 63141, United States
-
Ps0015 954
Skokie, Illinois, 60077, United States
-
Ps0015 965
Kew Gardens, New York, 11415, United States
-
Ps0015 966
Sandy Springs, Georgia, 30328, United States
-
Ps0015 969
High Point, North Carolina, 27262, United States
-
Ps0015 970
West Palm Beach, Florida, 33409, United States
-
Ps0015 971
Wilmington, North Carolina, 28405, United States
-
Ps0015 972
West Dundee, Illinois, 60118, United States
-
Ps0015 975
Santa Ana, California, 92701, United States
-
Ps0015 976
Tampa, Florida, 33614, United States
-
Ps0015 977
Pembroke Pines, Florida, 33028, United States
-
Ps0015 978
Pflugerville, Texas, 78660, United States
-
Ps0015 979
Dallas, Texas, 75246, United States
-
Ps0015 980
Bexley, Ohio, 43209, United States